📊 Get daily AI-graded market briefings
Morning + evening · AI impact + sector exposure · Free
LAST 30 DAYS
6 articles
AVG GRADE
NEUTRAL
score: 0.33
SENTIMENT
BEARISH
TOTAL VIEWS
42
CRSP Stock Analysis & AI Grade: NEUTRAL
6 articles analyzed · Sentiment: BEARISH · AI-powered equity research
RECENT COVERAGE · 6 ARTICLES
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
CRSP declined 2.08% in recent trading, closing at $46.54, while the broader market advanced. This represents a divergent move that...
Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are Underrating
Cathay Wood's $362 million position in CRSP Therapeutics signals conviction beyond consensus narratives around gene-editing science. The...
CRISPR Therapeutics: A Catalyst-Rich 12 Months Ahead (NASDAQ:CRSP)
CRISPR Therapeutics (CRSP) is positioned as a potential outperformer over the next 12 months, driven by a pipeline of near-term...
Here's Why CRISPR Therapeutics AG (CRSP) Fell More Than Broader Market
CRSP declined 5.45% in a single trading session, underperforming the broader market backdrop. This magnitude of single-day loss suggests...
CRISPR Therapeutics AG (CRSP) Stock Dips While Market Gains: Key Facts
CRSP declined 5.31% in the most recent session, underperforming a broader market rally. This divergence suggests sector-specific or...
CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
CRSP and VKTX represent divergent therapeutic strategies within the biotech space, with the former positioned in gene-editing...
RELATED TICKERS
E
ESEN Analytics
AI-powered equity research platform covering 5,000+ US equities. Our proprietary AI grading system (A+ to D scale) analyzes fundamentals, technicals, and news sentiment daily. Coverage data updated every 24 hours.
Learn about our methodology →
ⓘ AI-graded news coverage · Not investment advice